Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
SNN Network to hold a virtual event » 04:55
01/07/21
01/07
04:55
01/07/21
04:55
CTSDF

Converge Technology

$0.00 /

+ (+0.00%)

, CYPXF

EQ Inc

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.09 /

-0.18 (-3.42%)

, LXXGF

Lexagene Holdings

$0.00 /

+ (+0.00%)

, MCLDF

mCloud Technologies

$0.00 /

+ (+0.00%)

, NWVCF

EnWave

$0.00 /

+ (+0.00%)

, RILY

B. Riley Financial

$45.84 /

+2.51 (+5.79%)

, THBRF

Thunderbird Entertainment

$0.00 /

+ (+0.00%)

, VRNDF

Delta 9 Cannabis

$0.00 /

+ (+0.00%)

, VYGVF

Voyager Digital

$0.00 /

+ (+0.00%)

SNN Network Canada…

SNN Network Canada Virtual Event to be held on January 6-7.Webcast Link

ShowHide Related Items >><<
VYGVF Voyager Digital
$0.00 /

+ (+0.00%)

VRNDF Delta 9 Cannabis
$0.00 /

+ (+0.00%)

RILY B. Riley Financial
$45.84 /

+2.51 (+5.79%)

NWVCF EnWave
$0.00 /

+ (+0.00%)

LXXGF Lexagene Holdings
$0.00 /

+ (+0.00%)

EQ Equillium
$5.09 /

-0.18 (-3.42%)

CTSDF Converge Technology
$0.00 /

+ (+0.00%)

12/08/20 Raymond James
Converge Technology price target raised to C$4.75 from C$3.75 at Raymond James
10/05/20 Raymond James
Converge Technology price target raised to C$3.50 from C$2.80 at Raymond James
09/10/20 Raymond James
Converge Technology price target raised to C$2.80 from C$2.35 at Raymond James
04/29/20 Raymond James
Converge Technology initiated with an Outperform at Raymond James
CYPXF EQ Inc
$0.00 /

+ (+0.00%)

09/17/20 Canaccord
EQ Inc initiated with a Speculative Buy at Canaccord
EQ Equillium
$5.09 /

-0.18 (-3.42%)

11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
07/10/20 Stifel
Equillium transferred with Buy rating, $10 target at Stifel
LXXGF Lexagene Holdings
$0.00 /

+ (+0.00%)

06/17/20 Brookline
Lexagene Holdings initiated with a Buy at Brookline
04/28/20 Industrial Alliance
Lexagene Holdings initiated with a Speculative Buy at Industrial Alliance
MCLDF mCloud Technologies
$0.00 /

+ (+0.00%)

07/15/20 Alliance Global Partners
mCloud Technologies initiated with a Buy at Alliance Global Partners
NWVCF EnWave
$0.00 /

+ (+0.00%)

12/14/20 Raymond James
EnWave price target raised to C$1.60 from C$1.20 at Raymond James
04/24/20 Raymond James
EnWave downgraded to Market Perform from Outperform at Raymond James
RILY B. Riley Financial
$45.84 /

+2.51 (+5.79%)

THBRF Thunderbird Entertainment
$0.00 /

+ (+0.00%)

10/16/20 Canaccord
Thunderbird price target raised to C$3.25 from C$2.50 at Canaccord
VRNDF Delta 9 Cannabis
$0.00 /

+ (+0.00%)

05/20/20 Canaccord
Delta 9 Cannabis upgraded to Speculative Buy from Hold at Canaccord
VYGVF Voyager Digital
$0.00 /

+ (+0.00%)

12/17/20 Stifel
Stifel GMP starts Voyager Digital at Speculative Buy with C$3.30 price target
12/16/20 Stifel
Voyager Digital initiated with a Speculative Buy at Stifel
02/10/20 Benchmark
Voyager Digital initiated with a Speculative Buy at Benchmark
NWVCF EnWave
$0.00 /

+ (+0.00%)

EQ Equillium
$5.09 /

-0.18 (-3.42%)

  • 14
    Aug
VRNDF Delta 9 Cannabis
$0.00 /

+ (+0.00%)

RILY B. Riley Financial
$45.84 /

+2.51 (+5.79%)

EQ Equillium
$5.09 /

-0.18 (-3.42%)

Conference/Events
SNN Network to hold a virtual event » 09:45
01/06/21
01/06
09:45
01/06/21
09:45
CTSDF

Converge Technology

$0.00 /

+ (+0.00%)

, CYPXF

EQ Inc

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.29 /

+0.02 (+0.38%)

, LXXGF

Lexagene Holdings

$0.00 /

+ (+0.00%)

, MCLDF

mCloud Technologies

$0.00 /

+ (+0.00%)

, NWVCF

EnWave

$0.00 /

+ (+0.00%)

, RILY

B. Riley Financial

$43.34 /

+0.01 (+0.02%)

, THBRF

Thunderbird Entertainment

$0.00 /

+ (+0.00%)

, VRNDF

Delta 9 Cannabis

$0.00 /

+ (+0.00%)

, VYGVF

Voyager Digital

$0.00 /

+ (+0.00%)

SNN Network Canada…

SNN Network Canada Virtual Event to be held on January 6-7.Webcast Link

ShowHide Related Items >><<
VYGVF Voyager Digital
$0.00 /

+ (+0.00%)

VRNDF Delta 9 Cannabis
$0.00 /

+ (+0.00%)

RILY B. Riley Financial
$43.34 /

+0.01 (+0.02%)

NWVCF EnWave
$0.00 /

+ (+0.00%)

LXXGF Lexagene Holdings
$0.00 /

+ (+0.00%)

EQ Equillium
$5.29 /

+0.02 (+0.38%)

CTSDF Converge Technology
$0.00 /

+ (+0.00%)

12/08/20 Raymond James
Converge Technology price target raised to C$4.75 from C$3.75 at Raymond James
10/05/20 Raymond James
Converge Technology price target raised to C$3.50 from C$2.80 at Raymond James
09/10/20 Raymond James
Converge Technology price target raised to C$2.80 from C$2.35 at Raymond James
04/29/20 Raymond James
Converge Technology initiated with an Outperform at Raymond James
CYPXF EQ Inc
$0.00 /

+ (+0.00%)

09/17/20 Canaccord
EQ Inc initiated with a Speculative Buy at Canaccord
EQ Equillium
$5.29 /

+0.02 (+0.38%)

11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
07/10/20 Stifel
Equillium transferred with Buy rating, $10 target at Stifel
LXXGF Lexagene Holdings
$0.00 /

+ (+0.00%)

06/17/20 Brookline
Lexagene Holdings initiated with a Buy at Brookline
04/28/20 Industrial Alliance
Lexagene Holdings initiated with a Speculative Buy at Industrial Alliance
MCLDF mCloud Technologies
$0.00 /

+ (+0.00%)

07/15/20 Alliance Global Partners
mCloud Technologies initiated with a Buy at Alliance Global Partners
NWVCF EnWave
$0.00 /

+ (+0.00%)

12/14/20 Raymond James
EnWave price target raised to C$1.60 from C$1.20 at Raymond James
04/24/20 Raymond James
EnWave downgraded to Market Perform from Outperform at Raymond James
RILY B. Riley Financial
$43.34 /

+0.01 (+0.02%)

THBRF Thunderbird Entertainment
$0.00 /

+ (+0.00%)

10/16/20 Canaccord
Thunderbird price target raised to C$3.25 from C$2.50 at Canaccord
VRNDF Delta 9 Cannabis
$0.00 /

+ (+0.00%)

05/20/20 Canaccord
Delta 9 Cannabis upgraded to Speculative Buy from Hold at Canaccord
VYGVF Voyager Digital
$0.00 /

+ (+0.00%)

12/17/20 Stifel
Stifel GMP starts Voyager Digital at Speculative Buy with C$3.30 price target
12/16/20 Stifel
Voyager Digital initiated with a Speculative Buy at Stifel
02/10/20 Benchmark
Voyager Digital initiated with a Speculative Buy at Benchmark
NWVCF EnWave
$0.00 /

+ (+0.00%)

EQ Equillium
$5.29 /

+0.02 (+0.38%)

  • 14
    Aug
VRNDF Delta 9 Cannabis
$0.00 /

+ (+0.00%)

RILY B. Riley Financial
$43.34 /

+0.01 (+0.02%)

EQ Equillium
$5.29 /

+0.02 (+0.38%)

Over a month ago
Hot Stocks
Equillium appoints Dolca Thomas as CMO, EVP, R&D » 08:13
12/21/20
12/21
08:13
12/21/20
08:13
EQ

Equillium

$4.93 /

+0.12 (+2.49%)

Equillium announced the…

Equillium announced the appointment of Dolca Thomas, M.D., as its executive vice president of research and development and chief medical officer. Dr. Thomas joins Equillium from Principia Biopharma where she was chief medical officer focused on developing treatments for immune-mediated diseases.

ShowHide Related Items >><<
EQ Equillium
$4.93 /

+0.12 (+2.49%)

EQ Equillium
$4.93 /

+0.12 (+2.49%)

11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
07/10/20 Stifel
Equillium transferred with Buy rating, $10 target at Stifel
01/03/20 Stifel
Stifel says Incyte setback means Equillium may have most advanced aGVHD product
EQ Equillium
$4.93 /

+0.12 (+2.49%)

  • 14
    Aug
EQ Equillium
$4.93 /

+0.12 (+2.49%)

Hot Stocks
Equillium presents translational data on itolizumab » 08:41
12/07/20
12/07
08:41
12/07/20
08:41
EQ

Equillium

$4.88 /

-0.02 (-0.41%)

Equillium presented data…

Equillium presented data over the weekend demonstrating the impact of itolizumab on effector T cell function in graft-versus-host disease. The data was presented virtually at the 2020 American Society of Hematology Annual Meeting and Exposition being held December 5-8, 2020. GVHD is a severe multisystem complication that frequently occurs after hematopoietic stem cell transplantation when there is an upregulation of activated proinflammatory effector T cells resulting in the transplanted immune system attacking and damaging host tissues. There are currently no approved therapies to treat acute GVHD in the first-line setting. The CD6-ALCAM pathway promotes effector T cell activation, proliferation and trafficking, playing a central role in the autoimmune and inflammatory process. Itolizumab is an anti-CD6 monoclonal antibody that has been shown to potentially modulate T cell activity in GVHD. The study described in the oral presentation titled, "Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab", characterized CD6 expression levels and demonstrated the suppressive effect of itolizumab on the activity of CD4 and CD8 T cells from transplant patients with acute GVHD. Additional data presented in a poster reveals itolizumab's direct impact on activated Th1 and Th17 effector T cells shown through decreases of activation markers, cytokine release and CD6 surface expression.

ShowHide Related Items >><<
EQ Equillium
$4.88 /

-0.02 (-0.41%)

EQ Equillium
$4.88 /

-0.02 (-0.41%)

11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
07/10/20 Stifel
Equillium transferred with Buy rating, $10 target at Stifel
01/03/20 Stifel
Stifel says Incyte setback means Equillium may have most advanced aGVHD product
EQ Equillium
$4.88 /

-0.02 (-0.41%)

  • 14
    Aug
EQ Equillium
$4.88 /

-0.02 (-0.41%)

Conference/Events
Equillium to host virtual analyst day » 09:02
12/04/20
12/04
09:02
12/04/20
09:02
EQ

Equillium

$4.90 /

-0.1 (-2.00%)

Virtual Analyst Day to be…

Virtual Analyst Day to be held on December 4 at 9:30 am. Webcast Link

ShowHide Related Items >><<
EQ Equillium
$4.90 /

-0.1 (-2.00%)

EQ Equillium
$4.90 /

-0.1 (-2.00%)

11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
07/10/20 Stifel
Equillium transferred with Buy rating, $10 target at Stifel
01/03/20 Stifel
Stifel says Incyte setback means Equillium may have most advanced aGVHD product
EQ Equillium
$4.90 /

-0.1 (-2.00%)

  • 14
    Aug
EQ Equillium
$4.90 /

-0.1 (-2.00%)

Recommendations
Equillium price target lowered to $12 from $22 at H.C. Wainwright » 06:15
11/30/20
11/30
06:15
11/30/20
06:15
EQ

Equillium

$4.92 /

+0.02 (+0.41%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Equillium to $12 from $22 and reiterates a Buy rating on the shares after the company elected to place the proposed pivotal program to assess itolizumab in COVID-19 on hold. The analyst believes Equillium's decision may have been premature because long-term safety and durability of immunity data for the late-stage COVID-19 vaccines has not yet been generated, but appreciates the company's decision to "act conservatively and cautiously."

ShowHide Related Items >><<
EQ Equillium
$4.92 /

+0.02 (+0.41%)

EQ Equillium
$4.92 /

+0.02 (+0.41%)

07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
07/10/20 Stifel
Equillium transferred with Buy rating, $10 target at Stifel
01/03/20 Stifel
Stifel says Incyte setback means Equillium may have most advanced aGVHD product
EQ Equillium
$4.92 /

+0.02 (+0.41%)

  • 14
    Aug
EQ Equillium
$4.92 /

+0.02 (+0.41%)

Hot Stocks
Equillium not initiating EQUINOX Phase 3 trial of itolizumab 'at this time' » 08:04
11/25/20
11/25
08:04
11/25/20
08:04
EQ

Equillium

$5.08 /

-0.1 (-1.93%)

Equillium announced that…

Equillium announced that due to the rapidly evolving COVID-19 treatment landscape, the company will not initiate the EQUINOX Phase 3 clinical trial to evaluate itolizumab in hospitalized COVID-19 patients at this time. "Based on a thorough review of recent updates regarding the efficacy of new potential vaccines and other treatment options, we have made the strategic decision not to initiate our EQUINOX Phase 3 trial as previously planned. We are continuing to assess the rapidly evolving clinical and commercial landscape related to this pandemic and may consider other options to evaluate itolizumab in COVID-19 patients, including government research initiatives," said Bruce Steel, CEO of Equillium. "While this is a difficult decision given the current high rates of infection and significant unmet medical need, we believe it is prudent given the recent positive advancements by our biopharma colleagues to combat this serious pandemic. We greatly appreciate the support and effort of our trial investigators, clinical trial sites, and our Equillium team who played a vital role in preparing for the EQUINOX study, especially during this challenging time. Based on recent positive itolizumab interim clinical data in acute graft-versus-host disease we plan to prioritize our resources on expanding and accelerating this program, as well as advancing our lupus / lupus nephritis and uncontrolled asthma studies. We look forward to providing additional pipeline updates at our Analyst Day on Friday, December 4."

ShowHide Related Items >><<
EQ Equillium
$5.08 /

-0.1 (-1.93%)

EQ Equillium
$5.08 /

-0.1 (-1.93%)

07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
07/10/20 Stifel
Equillium transferred with Buy rating, $10 target at Stifel
01/03/20 Stifel
Stifel says Incyte setback means Equillium may have most advanced aGVHD product
EQ Equillium
$5.08 /

-0.1 (-1.93%)

  • 14
    Aug
EQ Equillium
$5.08 /

-0.1 (-1.93%)

On The Fly
Fly Intel: After-Hours Movers » 19:06
11/10/20
11/10
19:06
11/10/20
19:06
FUBO

FuboTV

$15.65 /

+1.01 (+6.90%)

, MYO

Myomo

$4.80 /

+0.07 (+1.48%)

, ONEM

1Life Healthcare

$32.84 /

+0.41 (+1.26%)

, AMRK

A-Mark Precious Metals

$29.24 /

+2.28 (+8.46%)

, BRKS

Brooks Automation

$59.43 /

-1.28 (-2.11%)

, SANM

Sanmina

$29.77 /

+1.1 (+3.84%)

, LYFT

Lyft

$36.07 /

-1.65 (-4.37%)

, EQ

Equillium

$3.47 /

-0.08 (-2.25%)

, ALC

Alcon

$64.76 /

-0.88 (-1.34%)

, CVET

Covetrus

$25.97 /

-0.62 (-2.33%)

, OSMT

Osmotica Pharmaceuticals

$5.90 /

-0.1 (-1.67%)

, DOX

Amdocs

$60.71 /

-0.06 (-0.10%)

, FPRX

Five Prime

$5.34 /

-0.14 (-2.55%)

, EGAN

eGain

$16.92 /

+0.42 (+2.55%)

, MODN

Model N

$35.47 /

-0.12 (-0.34%)

, GO

Grocery Outlet

$42.53 /

+1.31 (+3.18%)

, DDOG

Datadog

$92.42 /

-2.48 (-2.61%)

, PRPL

Purple Innovation

$25.30 /

-2.04 (-7.46%)

, KODK

Eastman Kodak

$6.70 /

+0.025 (+0.37%)

, HCAT

Health Catalyst

$36.81 /

+1 (+2.79%)

, RKT

Rocket Companies

$21.59 /

+0.11 (+0.51%)

, ACB

Aurora Cannabis

$8.27 /

-2.98 (-26.49%)

, VIE

Viela Bio

$36.96 /

+0.25 (+0.68%)

Check out this evening's…

ShowHide Related Items >><<
VIE Viela Bio
$36.96 /

+0.25 (+0.68%)

SANM Sanmina
$29.77 /

+1.1 (+3.84%)

RKT Rocket Companies
$21.59 /

+0.11 (+0.51%)

PRPL Purple Innovation
$25.30 /

-2.04 (-7.46%)

OSMT Osmotica Pharmaceuticals
$5.90 /

-0.1 (-1.67%)

ONEM 1Life Healthcare
$32.84 /

+0.41 (+1.26%)

MYO Myomo
$4.80 /

+0.07 (+1.48%)

MODN Model N
$35.47 /

-0.12 (-0.34%)

LYFT Lyft
$36.07 /

-1.65 (-4.37%)

KODK Eastman Kodak
$6.70 /

+0.025 (+0.37%)

HCAT Health Catalyst
$36.81 /

+1 (+2.79%)

GO Grocery Outlet
$42.53 /

+1.31 (+3.18%)

FUBO FuboTV
$15.65 /

+1.01 (+6.90%)

FPRX Five Prime
$5.34 /

-0.14 (-2.55%)

EQ Equillium
$3.47 /

-0.08 (-2.25%)

EGAN eGain
$16.92 /

+0.42 (+2.55%)

DOX Amdocs
$60.71 /

-0.06 (-0.10%)

DDOG Datadog
$92.42 /

-2.48 (-2.61%)

CVET Covetrus
$25.97 /

-0.62 (-2.33%)

AMRK A-Mark Precious Metals
$29.24 /

+2.28 (+8.46%)

ALC Alcon
$64.76 /

-0.88 (-1.34%)

ACB Aurora Cannabis
$8.27 /

-2.98 (-26.49%)

FUBO FuboTV
$15.65 /

+1.01 (+6.90%)

11/02/20
Fly Intel: Top five analyst initiations
11/02/20 Needham
FuboTV initiated with a Buy at Needham
11/02/20 Evercore ISI
FuboTV initiated with an Outperform at Evercore ISI
11/02/20 Roth Capital
FuboTV initiated with a Buy at Roth Capital
MYO Myomo
$4.80 /

+0.07 (+1.48%)

09/16/20 Roth Capital
Myomo provider status authorization 'an incremental positive,' says Roth Capital
09/16/20 Colliers
Myomo price target raised to $8 from $7 at Colliers
05/27/20
Myomo initiated with a Buy at Dougherty
03/23/20 Ascendiant
Myomo price target lowered to $15 from $45 at Ascendiant
ONEM 1Life Healthcare
$32.84 /

+0.41 (+1.26%)

10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Credit Suisse
1Life Healthcare initiated with an Outperform at Credit Suisse
10/14/20 Deutsche Bank
1Life Healthcare initiated with a Buy at Deutsche Bank
10/13/20 Citi
1Life Healthcare assumed with a Buy from Neutral at Citi
AMRK A-Mark Precious Metals
$29.24 /

+2.28 (+8.46%)

09/28/20 Roth Capital
A-Mark Precious Metals price target raised to $45 from $33 at Roth Capital
08/24/20
Fly Intel: Top five analyst initiations
08/24/20 Roth Capital
A-Mark Precious Metals initiated with a Buy at Roth Capital
BRKS Brooks Automation
$59.43 /

-1.28 (-2.11%)

11/09/20 KeyBanc
Brooks Automation initiated with an Overweight at KeyBanc
09/20/20 Stifel
Stifel gets more positive on Semi Cap Equipment, upgrades Brooks to Buy
09/20/20 Stifel
Brooks Automation upgraded to Buy from Hold at Stifel
08/04/20 Needham
Brooks Automation upgraded to Buy from Hold at Needham
SANM Sanmina
$29.77 /

+1.1 (+3.84%)

07/30/20 Craig-Hallum
Sanmina price target raised to $40 from $31 at Craig-Hallum
02/13/20 Citi
Cisco results slightly negative for EMS companies, says Citi
11/14/19 Citi
Cisco results negative for electronics manufacturing services, says Citi
LYFT Lyft
$36.07 /

-1.65 (-4.37%)

11/10/20 Truist
Lyft price target lowered to $44 from $49 at Truist
11/05/20 Deutsche Bank
Lyft price target raised to $55 from $52 at Deutsche Bank
11/04/20 Wedbush
Uber, Lyft get massive win with Prop 22 passing, overhang removed, says Wedbush
11/04/20 BofA
California vote helps ease 'a big uncertainty' for Uber, says BofA
EQ Equillium
$3.47 /

-0.08 (-2.25%)

07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
07/10/20 Stifel
Equillium transferred with Buy rating, $10 target at Stifel
01/03/20 Stifel
Stifel says Incyte setback means Equillium may have most advanced aGVHD product
ALC Alcon
$64.76 /

-0.88 (-1.34%)

10/14/20 UBS
Alcon price target raised to CHF 67 from CHF 63 at UBS
09/01/20 Berenberg
Alcon price target lowered to CHF 62 from CHF 64 at Berenberg
08/27/20 Societe Generale
Societe Generale downgrades Alcon to Sell, says recovery 'already over-priced'
08/27/20 Societe Generale
Alcon downgraded to Sell from Hold at Societe Generale
CVET Covetrus
$25.97 /

-0.62 (-2.33%)

09/16/20
Fly Intel: Top five analyst upgrades
09/16/20 Stifel
Covetrus upgraded to Buy with $26 price target at Stifel
09/16/20 Stifel
Covetrus upgraded to Buy from Hold at Stifel
08/12/20 Raymond James
Covetrus price target raised to $26 from $14 at Raymond James
OSMT Osmotica Pharmaceuticals
$5.90 /

-0.1 (-1.67%)

07/10/20 Truist
Osmotica Pharmaceuticals price target raised to $11 from $8 at SunTrust
07/09/20 RBC Capital
Osmotica price target raised to $12 from $10 at RBC Capital
03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
DOX Amdocs
$60.71 /

-0.06 (-0.10%)

02/05/20 Oppenheimer
Amdocs price target raised to $85 from $77 at Oppenheimer
11/15/19 Stifel
Amdocs price target raised to $75 from $70 at Stifel
FPRX Five Prime
$5.34 /

-0.14 (-2.55%)

09/22/20 Guggenheim
Five Prime upgraded to Buy at Guggenheim ahead of Phase 2 FIGHT results
09/22/20 Guggenheim
Five Prime upgraded to Buy from Neutral at Guggenheim
06/22/20 Wedbush
Five Prime upgraded to Outperform from Neutral at Wedbush
06/22/20 Wedbush
Five Prime upgraded to Outperform from Neutral at Wedbush
EGAN eGain
$16.92 /

+0.42 (+2.55%)

10/20/20 Berenberg
eGain initiated with a Buy at Berenberg
10/14/20 Benchmark
eGain share price may be benefiting from M&A speculation, says Benchmark
09/09/20
Fly Intel: Top five analyst initiations
09/09/20 DA Davidson
eGain initiated with a Buy at DA Davidson
MODN Model N
$35.47 /

-0.12 (-0.34%)

08/05/20 Craig-Hallum
Model N price target raised to $49.50 from $38 at Craig-Hallum
04/29/20 Truist
Model N initiated with a Buy at SunTrust
04/29/20 Truist
Model N initiated with a Buy at SunTrust
04/16/20 BTIG
Model N initiated with a Neutral at BTIG
GO Grocery Outlet
$42.53 /

+1.31 (+3.18%)

08/14/20 DA Davidson
Grocery Outlet initiated with a Buy at DA Davidson
08/14/20 DA Davidson
Grocery Outlet initiated with a Buy at DA Davidson
08/04/20 Deutsche Bank
Grocery Outlet price target raised to $47 from $43 at Deutsche Bank
07/30/20 MKM Partners
Grocery Outlet initiated with a Buy at MKM Partners
DDOG Datadog
$92.42 /

-2.48 (-2.61%)

11/05/20 Stifel
JFrog reported 'strong first print as a public company,' says Stifel
10/26/20 Stifel
SAP news impact may be company-specific for software sector, says Stifel
10/23/20 Barclays
Datadog price target raised to $136 from $126 at Barclays
10/20/20 Loop Capital
Datadog price target raised to $140 from $110 at Loop Capital
PRPL Purple Innovation
$25.30 /

-2.04 (-7.46%)

11/10/20 KeyBanc
Purple Innovation price target raised to $34 from $26 at KeyBanc
10/26/20 Raymond James
Purple Innovation price target raised to $36 from $28 at Raymond James
10/20/20 Craig-Hallum
Purple Innovation price target raised to $40 from $32 at Craig-Hallum
10/14/20 B. Riley Securities
Purple Innovation price target raised to $33 from $26 at B. Riley Securities
KODK Eastman Kodak
$6.70 /

+0.025 (+0.37%)

HCAT Health Catalyst
$36.81 /

+1 (+2.79%)

08/18/20 Guggenheim
Health Catalyst price target raised to $37 from $33 at Guggenheim
08/12/20 Truist
Health Catalyst price target raised to $43 from $36 at Truist
07/14/20 Citi
Health Catalyst initiated with a Buy at Citi
07/10/20 SVB Leerink
Health Catalyst price target raised to $40 from $32 at SVB Leerink
RKT Rocket Companies
$21.59 /

+0.11 (+0.51%)

11/06/20 Wolfe Research
Rocket Companies initiated with an Outperform at Wolfe Research
10/12/20 Keefe Bruyette
Rocket Companies initiated with a Market Perform at Keefe Bruyette
10/09/20 JPMorgan
Rocket Companies upgraded to Overweight on relative upside at JPMorgan
10/09/20 JPMorgan
Rocket Companies upgraded to Overweight from Neutral at JPMorgan
ACB Aurora Cannabis
$8.27 /

-2.98 (-26.49%)

11/10/20 CIBC
Aurora Cannabis price target raised to C$15 from C$12 at CIBC
11/10/20 Canaccord
Aurora Cannabis price target raised to C$11 from C$8.50 at Canaccord
11/09/20 Stifel
Stifel reviewing Hold rating for Aurora Cannabis after 'negative' report
10/28/20 Stifel
Aurora Cannabis price target lowered to C$3.60 from C$10.50 at Stifel
VIE Viela Bio
$36.96 /

+0.25 (+0.68%)

10/26/20 H.C. Wainwright
Viela Bio price target lowered to $75 from $82 at H.C. Wainwright
07/15/20 Goldman Sachs
Viela Bio upgraded to Neutral from Sell at Goldman Sachs
06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/12/20 H.C. Wainwright
Viela Bio price target raised to $76 from $70 at H.C. Wainwright
VIE Viela Bio
$36.96 /

+0.25 (+0.68%)

SANM Sanmina
$29.77 /

+1.1 (+3.84%)

RKT Rocket Companies
$21.59 /

+0.11 (+0.51%)

PRPL Purple Innovation
$25.30 /

-2.04 (-7.46%)

OSMT Osmotica Pharmaceuticals
$5.90 /

-0.1 (-1.67%)

ONEM 1Life Healthcare
$32.84 /

+0.41 (+1.26%)

MYO Myomo
$4.80 /

+0.07 (+1.48%)

MODN Model N
$35.47 /

-0.12 (-0.34%)

LYFT Lyft
$36.07 /

-1.65 (-4.37%)

KODK Eastman Kodak
$6.70 /

+0.025 (+0.37%)

HCAT Health Catalyst
$36.81 /

+1 (+2.79%)

GO Grocery Outlet
$42.53 /

+1.31 (+3.18%)

FUBO FuboTV
$15.65 /

+1.01 (+6.90%)

FPRX Five Prime
$5.34 /

-0.14 (-2.55%)

EQ Equillium
$3.47 /

-0.08 (-2.25%)

EGAN eGain
$16.92 /

+0.42 (+2.55%)

DOX Amdocs
$60.71 /

-0.06 (-0.10%)

DDOG Datadog
$92.42 /

-2.48 (-2.61%)

CVET Covetrus
$25.97 /

-0.62 (-2.33%)

BRKS Brooks Automation
$59.43 /

-1.28 (-2.11%)

AMRK A-Mark Precious Metals
$29.24 /

+2.28 (+8.46%)

ALC Alcon
$64.76 /

-0.88 (-1.34%)

ACB Aurora Cannabis
$8.27 /

-2.98 (-26.49%)

  • 11
    Nov
  • 08
    Oct
  • 10
    Sep
  • 14
    Aug
  • 13
    Aug
  • 06
    Aug
  • 14
    Jul
  • 25
    Jun
  • 28
    May
  • 15
    May
  • 23
    Apr
  • 30
    Jan
  • 31
    Jan
  • 09
    Jan
  • 15
    Nov
RKT Rocket Companies
$21.59 /

+0.11 (+0.51%)

LYFT Lyft
$36.07 /

-1.65 (-4.37%)

KODK Eastman Kodak
$6.70 /

+0.025 (+0.37%)

DOX Amdocs
$60.71 /

-0.06 (-0.10%)

ACB Aurora Cannabis
$8.27 /

-2.98 (-26.49%)

SANM Sanmina
$29.77 /

+1.1 (+3.84%)

RKT Rocket Companies
$21.59 /

+0.11 (+0.51%)

PRPL Purple Innovation
$25.30 /

-2.04 (-7.46%)

OSMT Osmotica Pharmaceuticals
$5.90 /

-0.1 (-1.67%)

ONEM 1Life Healthcare
$32.84 /

+0.41 (+1.26%)

MYO Myomo
$4.80 /

+0.07 (+1.48%)

MODN Model N
$35.47 /

-0.12 (-0.34%)

LYFT Lyft
$36.07 /

-1.65 (-4.37%)

KODK Eastman Kodak
$6.70 /

+0.025 (+0.37%)

HCAT Health Catalyst
$36.81 /

+1 (+2.79%)

GO Grocery Outlet
$42.53 /

+1.31 (+3.18%)

FUBO FuboTV
$15.65 /

+1.01 (+6.90%)

FPRX Five Prime
$5.34 /

-0.14 (-2.55%)

EQ Equillium
$3.47 /

-0.08 (-2.25%)

DDOG Datadog
$92.42 /

-2.48 (-2.61%)

CVET Covetrus
$25.97 /

-0.62 (-2.33%)

BRKS Brooks Automation
$59.43 /

-1.28 (-2.11%)

AMRK A-Mark Precious Metals
$29.24 /

+2.28 (+8.46%)

ACB Aurora Cannabis
$8.27 /

-2.98 (-26.49%)

VIE Viela Bio
$36.96 /

+0.25 (+0.68%)

RKT Rocket Companies
$21.59 /

+0.11 (+0.51%)

PRPL Purple Innovation
$25.30 /

-2.04 (-7.46%)

ONEM 1Life Healthcare
$32.84 /

+0.41 (+1.26%)

LYFT Lyft
$36.07 /

-1.65 (-4.37%)

KODK Eastman Kodak
$6.70 /

+0.025 (+0.37%)

FUBO FuboTV
$15.65 /

+1.01 (+6.90%)

DDOG Datadog
$92.42 /

-2.48 (-2.61%)

ALC Alcon
$64.76 /

-0.88 (-1.34%)

ACB Aurora Cannabis
$8.27 /

-2.98 (-26.49%)

Earnings
Equillium reports Q3 EPS (31c), consensus (40c) » 17:32
11/10/20
11/10
17:32
11/10/20
17:32
EQ

Equillium

$3.47 /

-0.08 (-2.25%)

Equillium held cash, cash…

Equillium held cash, cash equivalents and short-term investments totaling $90.5M at September 30, compared to $53.1M at December 31, 2019. The increase in cash was driven by $53.8 million in total net proceeds raised from equity financings in 2020 through September 30. "We continue to make significant progress towards our goal of bringing itolizumab to patients suffering from a range of severe immuno-inflammatory disorders," said Bruce Steel, chief executive officer of Equillium. "We are well positioned to continue advancing our core trials including the Phase 1b EQUATE trial in acute graft-versus-host disease (aGVHD) where we recently reported positive response rates across the first three dose cohorts, as well as our Phase 1b EQUIP and EQUALISE trials in uncontrolled asthma and lupus nephritis, respectively. In parallel, we are poised to initiate the global Phase 3 EQUINOX trial of itolizumab in hospitalized COVID-19 patients during this quarter. We look forward to sharing additional updates at our upcoming Analyst Day in December."

ShowHide Related Items >><<
EQ Equillium
$3.47 /

-0.08 (-2.25%)

EQ Equillium
$3.47 /

-0.08 (-2.25%)

07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
07/10/20 Stifel
Equillium transferred with Buy rating, $10 target at Stifel
01/03/20 Stifel
Stifel says Incyte setback means Equillium may have most advanced aGVHD product
EQ Equillium
$3.47 /

-0.08 (-2.25%)

  • 14
    Aug
EQ Equillium
$3.47 /

-0.08 (-2.25%)

Hot Stocks
Equillium announces interim data of itolizumab in aGVHD » 08:37
11/06/20
11/06
08:37
11/06/20
08:37
EQ

Equillium

$4.88 /

-0.12 (-2.40%)

Equillium announced…

Equillium announced positive interim data from the third cohort of the Phase 1b open label, dose escalation study of itolizumab in the first-line treatment of acute graft-versus-host disease. The EQUATE trial is evaluating itolizumab in severe aGVHD patients concomitant with standard of care, which is typically comprised of high dose corticosteroids, as no other therapeutics are currently approved for this indication. Equillium anticipates reporting topline data across all cohorts from the Phase 1b portion of the EQUATE trial during the first half of 2021 and is accelerating plans for further development of itolizumab in graft-versus-host disease. In the EQUATE trial, the overall response rate across the first three dose cohorts was 80%, and seven of eight patients responding achieved a complete response and one patient achieved a very good partial response by Day 29. Responses observed have been rapid, with most patients achieving a CR within the first 15 days, and durable as patients in the first two cohorts have maintained responses through Day 57. To date, adverse events reported with the EQUATE trial have been consistent with the safety profile previously reported for itolizumab and those common in the aGVHD patient population. In review of the totality of safety, efficacy and pharmacodynamic data, the independent data monitoring committee has recommended to expand cohort 3 and proceed forward with enrollment. Equillium has received fast track designation from the FDA for the treatment of itolizumab in patients with aGVHD and orphan drug designations from the FDA for both the prevention and treatment of aGVHD. Equillium plans to provide additional updates on the program at its upcoming analyst day on December 4, 2020.

ShowHide Related Items >><<
EQ Equillium
$4.88 /

-0.12 (-2.40%)

EQ Equillium
$4.88 /

-0.12 (-2.40%)

07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
07/10/20 Stifel
Equillium transferred with Buy rating, $10 target at Stifel
01/03/20 Stifel
Stifel says Incyte setback means Equillium may have most advanced aGVHD product
EQ Equillium
$4.88 /

-0.12 (-2.40%)

  • 14
    Aug
EQ Equillium
$4.88 /

-0.12 (-2.40%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.